Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Stock Plummets 24 Percent on Lackluster Q2 Report

NEW YORK (GenomeWeb News) - Shares in Molecular Devices were down 24 percent, or $6.88, to $22.16 in mid-afternoon trading today after the company reported lackluster results for its second quarter.

As GenomeWeb News reported today, Molecular Devices reported a net loss of $460,000 for the quarter, compared to a profit year over year of $3.7 million.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.